Maximizing Pipeline Value Through Integrated Drug Development: How The Accelerator™ Drug Development Model Enhances eNPV

In today’s rapidly evolving biotech and biopharma landscape, bringing a new therapy to market has never been more complex. Development costs continue to climb, timelines are stretching longer, and competition is intensifying at both local and global levels. Amid these pressures, fragmentation across multiple vendors remains a critical obstacle—slowing progress, increasing risk, and limiting overall success. A new white paper from Thermo Fisher Scientific, validated through independent research conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD), demonstrates how a fully integrated model that unites CDMO and CRO services can significantly enhance expected net present value (eNPV) while accelerating development timelines.

The research quantifies the financial impact of integration, showing that unified CDMO and CRO services can generate up to $62.9 million in added value for monoclonal antibodies and $25.1 million for small molecules in Phase III trials. Drawing on real-world data from the first comprehensive study of its kind, the findings reveal measurable gains in time savings, cost efficiency, and return on investment—delivering returns of up to 100x. For emerging biotech companies, this integrated approach can accelerate the path to funding or acquisition, while global biopharma organizations can better manage increasingly complex portfolios. Through the Accelerator™ Drug Development framework, integration reduces handoffs, connects critical data streams, and enables faster, more predictable outcomes at every stage. With each month saved potentially representing up to $8 million in additional revenue opportunity, a streamlined, single-partner model offers a powerful way to compress timelines, improve decision-making, and maximize long-term pipeline value.